Hims & Hers Health, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions ...

Headlines,Hims & Hers Health Surpasses Earnings Expectations,Strong Revenue Growth Drives Positive Stock Movement,Analysts ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Fastly (FSLY) stock has been one of the worst-performers this year as the company’s growth has decelerated and losses have ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...

TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research ...

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...